Matinas BioPharma CDO resigns; CMO and VP Clinical Dev to assume duties

Matinas BioPharma Holdings, Inc.

Chief Development Officer Theresa Matkovits resigned effective October 23, 2024, to pursue another opportunity.
Resignation not due to material disagreement or change in company direction.
James J. Ferguson (CMO) and Susan Johansson (VP Clinical Dev) will fill her responsibilities.
Company continues to work toward partnership on MAT2203, its oral amphotericin B formulation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.